32 studies found for:    "Chronic inflammatory demyelinating polyneuropathy"
Show Display Options
RSS Create an RSS feed from your search for:
"Chronic inflammatory demyelinating polyneuropathy"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: NPB-01
2 Unknown  Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention:
3 Withdrawn High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Cyclophosphamide
4 Completed
Has Results
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: 10% liquid formulation of human immunoglobulin
5 Completed Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Conditions: CIDP;   Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: lipoic acid
6 Active, not recruiting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Polyradiculoneuropathy
Interventions: Biological: IgPro20;   Biological: Placebo;   Biological: IgPro10
7 Enrolling by invitation Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP);   Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Biological: IgPro20
8 Completed Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: Interferon Beta-1a
9 Active, not recruiting Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Drug: Fingolimod;   Drug: Placebo Comparator
10 Recruiting Subcutaneous Immunoglobulin for CIDP
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Immune Globulin Subcutaneous (Human)
11 Recruiting IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Intravenous Immunoglobulin
12 Completed Effect of Resistance and Aerobic Exercise in CIDP or MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy
Interventions: Other: Resistance training;   Other: Aerobic training
13 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Demyelinating Diseases;   Paraproteinemias
Intervention: Drug: intravenous immunoglobulin (IVIg)
14 Withdrawn Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: H.P. Acthar® Gel
15 Recruiting IVIg for Demyelination in Diabetes Mellitus
Conditions: Peripheral Neuropathy;   Diabetes Mellitus;   Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Drug: 10% intravenous immunoglobulin (IVIg);   Drug: 0.9% sodium chloride
16 Completed Immunoglobulin Dosage and Administration Form in CIDP and MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy;   Hemolytic Anemia
Intervention: Drug: Immunoglobulins
17 Enrolling by invitation MRI in Diagnosing and Monitoring CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention:
18 Recruiting Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: I10E
19 Recruiting Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: I10E
20 Recruiting Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Biological: HYQVIA;   Biological: 0.25% albumin placebo solution with rHuPH20;   Biological: IGIV

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Indicates status has not been verified in more than two years